Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
110 Leser
Artikel bewerten:
(0)

VacChina 2011 International Conference Meets in Shanghai This November

SHANGHAI, Oct. 9, 2011 /PRNewswire-Asia/ -- Vaccines made in China will now be supplied through United Nations (UN) agencies to developing countries, after recognition from the World Health Organisation (WHO) that China's State Food and Drug Administration (SFDA) has complied with international standards for vaccine regulation. The acknowledgement on China's regulatory system is a precondition that could lead to the UN purchasing individual vaccines from Chinese vaccine makers. For this to occur, the manufacturers also have to pass the approval for China's new version of GMP (Good Manufacturing Practice) for the Chinese pharmaceutical industry that was released at the end of February. On the other hand, China's vaccine industry is driven by novel technologies, especially by recent technological advances in vaccine research, production and distribution.

Organized by Global Leaders Institute, more than 300 of the world's vaccine business leaders, researchers, policy makers, and advocates will be in Shanghai this November 29 and 30 attending VacChina 2011, the only international meeting in China devoted to vaccine development opportunity in China. The objective of this conference is to provide communication, education and networking opportunities for business leaders and scientists engaged in vaccine development whether in academia, biotech or industry.

This year's anniversary conference features a workshop on Vaccine Manufacturing and WHO pre-qualification. The workshop will focus on the technologies and challenges of vaccine manufacturing in today's marketplace including quality, safety, policy, and examples from the industry. Besides, VacChina 2011 provides a comprehensive, in-depth analysis of China's vaccine market, new vaccine targets and methods of delivery, regulatory and funding initiatives, as well as following issues:

  • WHO pre-qualification requirements and details
  • Updates on cGMP and related policies
  • Future trends in vaccine discovery & new vaccines
  • Human vaccines focusing on infectious diseases, bacterial & viral
  • Single use applications in vaccine process development
  • Advances in technology for the purification and manufacturing of vaccines
  • The development of therapeutic vaccines
  • The commercial & business development of novel adjuvant vaccines

For further information and the opportunity to register online please visit: vac.globaleaders.com

Or contact Daniel Chen via e-mail daniel.chen@globaleaders.com or call at 8621-32516046

About Global Leaders Institute

Global Leaders Institute (GLI) is the producer and organizer of top-level business events. We focus on the development and operation of the strategic, market leading business conference. We focus on the specialty spirit and professional attainment. We focus on value creation for our client. We provide 60 annual conferences across energy, finance, transportation, life science, real estate, telecom and media, etc. each year.

SOURCE Global Leaders Institute

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2011 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.